Judge Dismissed Investor Lawsuit Against Inari Medical
A New York federal judge cleared Inari Medical of allegations regarding unlawful kickbacks to providers.
Updated on Sept. 24, 2026 in Healthcare
Live Poll
Should investors be permitted to sue companies based on the disclosure of a federal investigation?
A federal judge in New York dismissed a proposed investor class action lawsuit against Inari Medical Inc. The case had alleged that company share prices dropped following disclosures regarding a federal investigation into anti-kickback compliance.
Why it matters
The dismissal resolves claims that the company misled investors by failing to disclose illegal payments to healthcare providers. The court ruled that the plaintiffs failed to plausibly demonstrate that such kickbacks occurred.
A federal court ruling dismissed a pending class action suit after finding no plausible evidence of kickbacks. The total number of affected investor claims was dismissed in this single legal action.
The players
Inari Medical Inc.
This medical device company specializes in developing products for the treatment of venous and other vascular diseases.
The details
The lawsuit centered on a decline in Inari Medical share prices linked to revelations about a probe into federal anti-kickback law compliance. Following the court's review, the judge determined the complaint lacked sufficient evidence to show the firm engaged in unlawful provider payments.
Timeline
September 23, 2026: A federal judge dismissed the proposed investor class action lawsuit.
Market Landscape
This case reflects the ongoing scrutiny of medical device manufacturers regarding their interactions with healthcare providers under the federal Anti-Kickback Statute. Corporate transparency in clinical and sales operations remains a critical focus for investors navigating potential regulatory risks.
The dismissal of this lawsuit reduces the immediate legal uncertainty surrounding Inari Medical Inc. for shareholders and stakeholders. Consumers of medical services should note that the court did not find evidence of improper billing or kickback practices in this specific case.
The takeaway
Legal challenges regarding compliance can significantly affect investor confidence and market valuation for medical companies. Stakeholders should continue to monitor regulatory updates to understand how evolving enforcement of anti-kickback laws impacts corporate operations.
Further reading
For more on industry oversight, see our coverage of Healthcare.
Source note: This article includes information reported by Law360.
Live Poll
Should investors be permitted to sue companies based on the disclosure of a federal investigation?
